Upgrade for detailed insurance, legislation, and other documents analytics for individual cases; real-time analysis of the datasets from your EHR, CRM, ERP, or other software; and more Enterprise Features.
Represents 0.1 mg of ranibizumab-eqrn (Cimerli™), a biosimilar to Lucentis, used to treat various eye conditions by inhibiting vascular endothelial growth factor (VEGF).
2025 HCPCS code Q5118
Biosimilar bevacizumab-bvzr (Zirabev), 10 mg injection for intravenous infusion.
2025 HCPCS code Q5119
Rituximab-pvvr injection, 10 mg
2025 HCPCS code Q5120
This code represents 0.5 mg of Ziextenzo (pegfilgrastim-bmez), a biosimilar to pegfilgrastim, used to reduce infection risk in cancer patients receiving myelosuppressive chemotherapy.
Injection, pegfilgrastim-fpgk (Stimufend), biosimilar, 0.5 mg; a leukocyte growth factor used to reduce infection risk in patients undergoing myelosuppressive chemotherapy.
Инъекция, бевацизумаб с добавлением (Vegzelma), биоаналог, 10 мг.
2025 HCPCS code Q5128
<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">يمثل 0.1 ملغ من ranibizumab-eqrn (Cimerli™)، وهو بديل حيوي لـ Lucentis، يستخدم لعلاج أمراض العين المختلفة عن طريق تثبيط عامل نمو بطانة الأوعية الدموية (VEGF).</a>
2025 HCPCS code Q5129
주사제, 베바시주맙-ADCD (베젤마), 바이오시밀러, 10mg.
2025 HCPCS code Q5129
الحقن، إضافة بيفاسيزوماب (فيغزيلما)، بديل حيوي، 10 ملغ.
2025 HCPCS code Q5129
Tiêm, bevacizumab-adcd (Vegzelma), tương tự sinh học, 10 mg.
<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Представляет собой 0,1 мг ранибизумаба-экрна (Cimerli™), биоаналогичного препарату Lucentis, который используется для лечения различных заболеваний глаз путем ингибирования фактора роста эндотелия сосудов (VEGF).</a>
2025 HCPCS code Q5128
<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Representa 0,1 mg de ranibizumab-eqrn (Cimerli™), un biosimilar a Lucentis, que se usa para tratar diversas afecciones oculares al inhibir el factor de crecimiento endotelial vascular (VEGF).</a>
2025 HCPCS code Q5114
Tiêm, trastuzumab-dkst, tương tự sinh học, (Ogivri), 10 mg
2025 HCPCS code Q5128
<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Đại diện cho 0,1 mg ranibizumab-eqrn (Cimerli™), một chất tương tự sinh học với Lucentis, được sử dụng để điều trị các tình trạng mắt khác nhau bằng cách ức chế yếu tố tăng trưởng nội mô mạch máu (VEGF).</a>
2025 HCPCS code Q5128
<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Kinakatawan sa 0.1 mg ng ranibizumab-eqrn (Cimerli™), isang biosimilar sa Lucentis, na ginagamit upang gamutin ang iba't ibang mga kondisyon ng mata sa pamamagitan ng pagpigil sa vascular endothelial growth factor (VEGF).</a>
2025 HCPCS code Q5128
<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">Représente 0,1 mg de ranibizumab-eqrn (Cimerli™), un biosimilaire au Lucentis, utilisé pour traiter diverses affections oculaires en inhibant le facteur de croissance endothélial vasculaire (VEGF).</a>
2025 HCPCS code Q5128
<a href="../medical-coding/reference/VEGF" target="_blank" title="Medical Code VEGF 2025">혈관 내피 성장 인자 (VEGF) 를 억제하여 다양한 안구 질환을 치료하는 데 사용되는 루센티스의 바이오시밀러인 라니비주맙-eqrn (Cimerli™) 0.1mg을 나타냅니다.</a>
Continue with Personal Account
Thank you for exploring iFrame ♥ Please subscribe for unlimited access to our top-tier AI model, which directly supports our dedicated knowledge creators maintaining an ad-free internet experience.